AUTHORS
Seungwon An, PhD, Grace Charan, MS2, Dolores Mahmud, PhD3, Youngmin Park, MS4, Amudha Ganapathy, PhD5, Al Rabee Kassis, MD6, Elena Tepak, BS7, Damiano Rondelli, MD8, Nadim Mahmud, MD, PhD, MBA9
AFFILIATIONS
1 UI Health Blood & Marrow Transplantation Program, University of Illinois Hospital and Health Sciences, Chicago, Illinois, United States
2 UI Health Blood & Marrow Transplantation Program, University of Illinois Hospital and Health Sciences, Chicago, Illinois, United States
3 University of Illinois Chicago, Chicago, Illinois, United States
4 UI Health Blood & Marrow Transplantation Program, University of Illinois Hospital and Health Sciences, Chicago, Illinois, United States
5 University of Illinois Chicago, Chicago, Illinois, United States
6 University of Illinois Chicago, Chicago, Illinois, United States
7 UI Health Blood & Marrow Transplantation Program, University of Illinois Hospital and Health Sciences, Chicago, Illinois, United States
8 UI Health Blood & Marrow Transplantation Program, University of Illinois Hospital and Health Sciences, Chicago, IL, United States, University of Illinois Chicago, Chicago, Illinois, United States
9 UI Health Blood & Marrow Transplantation Program, University of Illinois Hospital and Health Sciences, Chicago, IL, United States, University of Illinois Chicago, Chicago, Illinois, United States
ABSTRACT
Cryopreservation enables long-term storage of hematopoietic stem and progenitor cell (HSPC) grafts; however, the effect of prolonged storage on functional potency remains incompletely defined. We evaluated 52 cryopreserved HSPC graft aliquots, including 33 autologous and 19 allogeneic products stored in liquid nitrogen for up to 14 years. Post-thaw analyses included total nucleated cell (TNC) and viable CD34? cell recovery, viability, mitochondrial membrane potential (MMP), colony-forming unit (CFU) capacity, xenotransplantation into NSG mice, and clinical hematopoietic recovery following transplantation in human patients. Autologous HSPC grafts were obtained from patients previously exposed to cytotoxic therapy, whereas allogeneic HSPC grafts were obtained from healthy, cytotoxic therapy–naïve donors.
TNC recovery declined with increasing storage duration, from 87.6% ± 2.31% in allogeneic grafts stored for <1 year to 48.3% ± 8.28% (p = 0.007) in allogeneic grafts stored for >10 years and 61.2% ± 5.56% (p = 0.002) in autologous grafts stored for >10 years. In contrast, viable CD34? cell recovery remained above 60% after 10 years in both graft types. CFU recovery declined progressively with prolonged storage, particularly in allogeneic grafts, and was accompanied by increased apoptosis and reduced MMP. These changes were not observed in allogeneic grafts stored for <1 year, suggesting an effect of prolonged cryostorage rather than baseline graft characteristics.
Long-stored autologous grafts demonstrated superior preservation of MMP, viable TNC recovery, viable CD34? cell recovery, and clonogenic activity compared with similarly stored allogeneic grafts, indicating greater resistance to long-term cryostorage. Xenotransplantation studies demonstrated preserved hematopoietic engraftment after 10 years of storage in both graft types, with comparable human CD45? bone marrow chimerism. However, recipients of autologous grafts exhibited higher splenic chimerism and greater recovery of human CD33? myeloid cells, suggesting differences in progenitor function or lineage output despite similar bone marrow engraftment. Clinically, autologous grafts stored for up to 10 years supported successful hematopoietic recovery when adequate CD34? cell doses were infused.
These findings suggest that long-term cryopreserved HSPC grafts retain hematopoietic reconstitution capacity despite progressive loss of clonogenic function. Our data further indicates a potential inflection point at approximately 5 years of storage, beyond which functional potency declines more rapidly, particularly in allogeneic grafts. Importantly, conventional flow cytometric assessment of CD34? cell viability alone did not accurately predict graft function after prolonged cryostorage. Instead, integrated assessment incorporating cell viability, mitochondrial fitness, clonogenic capacity, and in vivo engraftment provided a more comprehensive evaluation of graft potency. Ongoing single-cell RNA sequencing studies will determine whether molecular signatures associated with prior cytotoxic therapy contribute to the enhanced resilience observed in long-term cryopreserved autologous HSPC grafts.
DISCLOSURES
Nadim Mahmud, MD, PhD, MBA: No relevant conflicts of interest to declare.